Sector News

Sanofi starts on viral vector facility as its R&D focus shifts to gene therapies

October 23, 2019
Life sciences

Sanofi is playing catch-up in gene therapy, but new CEO Paul Hudson is taking quick steps to close the gap. A reorganization of the R&D unit is intended to pivot the drugmaker toward immuno-oncology drugs and gene therapies.

And to hasten the transition, the company is retrofitting a vaccine plant in France into a gene therapy manufacturing operation.

A spokesman Monday confirmed Sanofi is preparing teams at its Lyon-Gerland site to work on vector-based gene therapies. Hudson spoke about the project in an interview with BioPharma Dive. The drugmaker expects the facility to be operational a year from now.

Sanofi has invested about €25 million in the Lyon-Gerland site over the last five years. In 2013, the drugmaker struck a deal with France’s Transgene to share the cost of a €10 million facility there to manufacture Transgene’s immuno-oncology therapies.

The Lyon vaccine facility is being retrofitted even as Sanofi this summer reworked its gene therapy partnership with Voyager Therapeutics. Sanofi dumped two programs it has started with Voyager, and now the two will develop adeno-associated virus capsids —the protein shells of the virus—for the delivery of gene therapies. Sanofi gets the exclusive option to use these capsids to deliver treatments for up to two non-CNS diseases.

The project also comes as Sanofi has been upgrading other parts of its manufacturing network for the future. Last week, it opened a new biologics plant in Massachusetts that it considers its prototype plant of the future. In the digitally enabled manufacturing facility, all manufacturing stages are controlled through analytical processes that are forecast to avoid variations.

Plant operators also have access to data analytics or augmented reality solutions that can help them make real-time decisions and adjustments. He said the remade plant is 80 times more productive while also reducing energy use and emissions by 80%.

As for gene therapy production, Sanofi is following other companies such bluebird bio and Gilead’s Kite Pharma in building viral vector manufacturing facilities to serve their gene therapy or CAR-T development programs, which are much further along than Sanofi’s.

By Eric Palmer

Source: Fierce Pharma

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend